实用肝脏病杂志 ›› 2018, Vol. 21 ›› Issue (6): 903-906.doi: 10.3969/j.issn.1672-5069.2018.06.019

• 肝硬化 • 上一篇    下一篇

恩替卡韦联合复方鳖甲软肝片治疗乙型肝炎肝硬化患者疗效及转归研究*

安红杰, 周东方   

  1. 065000河北省廊坊市 中国石油天然气集团公司中心医院感染病科(安红杰); 河北医科大学第三临床医院感染二科(周东方)
  • 收稿日期:2018-01-19 出版日期:2018-11-10 发布日期:2018-12-25
  • 作者简介:安红杰,女,41岁,医学硕士,副主任医师。E-mail:zhangsen1976@sina.com
  • 基金资助:
    *河北省自然科学基金资助项目(编号:2015008892)

Efficacy of entecavir and Chinese herbal medicine combination therapy in patients with hepatitis B-induced liver cirrhosis An

Hongjie, Zhou Dongfang.   

  1. Department of Infectious Diseases,Central Hospital,Affiliated to China National Petroleum Corporation,Langfang 065000,Hebei Province,China
  • Received:2018-01-19 Online:2018-11-10 Published:2018-12-25

摘要: 目的 研究应用恩替卡韦(ETV)联合复方鳖甲软肝片治疗乙型肝炎肝硬化患者的疗效及其对疾病转归的影响。方法 2014年1月~2016年12月我院收治的乙型肝炎肝硬化患者76例,采用随机数字表法将患者分为对照组36例和观察组40例,分别给予ETV或ETV联合复方鳖甲软肝片治疗,观察12 m月。采用 PCR法定量检测血清HBV DNA载量,采用放射免疫法检测血清透明质酸(HA)、Ⅲ型前胶原(PⅢP)、层粘连蛋白(LN)和Ⅳ型胶原(CⅣ),常规行血生化和Fibroscan检查。结果 在治疗12 m末,观察组血清TBIL为(19.7±13.4) μmol/L,ALT水平为(28.3±9.4) U/L,均显著低于对照组的[(23.2±13.8) μmol/L和(53.6±10.2) U/L,P<0.05],观察组血清ALB水平为(37.2±5.6) g/L,PTA为(91.1±11.2) %,显著高于对照组[(34.7±6.1) g/L和(81.4±10.5) %,P<0.05];观察组CTP评分为(6.3±1.2),显著低于对照组的[(8.1±1.4),P<0.05],肝脏硬度检测(LSM)为(16.5±12.2) kPa,也显著低于对照组的[(22.7±14.4) kPa,P<0.05];观察组血清HA水平为(89.2±43.1) μg/L,PⅢP为(119.7±60.8) μg/L,LN为(98.7±30.2) μg/L,CⅣ为(102.6±29.7) μg/L,均低于对照组[分别为(184.3±58.2) μg/L、(254.5±74.7) μg/L、(140.8±39.7) μg/L、(165.7±41.2) μg/L,P<0.05];观察组血清HBV DNA阴转率为97.5%(39/40),与对照组的94.4%(34/36)比,差异无统计学意义(P>0.05),观察组血清HBV DNA载量为(3.2±0.3)log10 copies/ml,与对照组的(3.5±0.4)log10 copies/ml比,无显著性差异(P>0.05);观察组腹水、肝性脑病、消化道出血和肝细胞癌发生率分别为17.5%、5.0%、10.0%和2.5%,显著低于对照组的52.7%、13.8%、16.7%和11.1% (P<0.05);在观察的12 m内,观察组无死亡病例,而对照组死亡3例(8.3%)。结论 应用ETV联合复方鳖甲软肝片治疗能够明显改善乙型肝炎肝硬化患者肝功能指标,降低血清肝纤维化指标,改善预后。

关键词: 肝硬化, 乙型肝炎, 恩替卡韦, 复方鳖甲软肝片, 疗效, 转归

Abstract: Objective To investigate the efficacy of entecavir(ETV) and Fufang Biejiaruanganpian,a Chinese herbal medicine compound,combination therapy in patients with hepatitis B-induced liver cirrhosis. Methods 76 patients with hepatitis B liver cirrhosis were recruited in our hospital between January 2014 and December 2016. The patients with liver cirrhosis were randomly divided into control group (n=36) and observation group(n=40),receiving ETV or ETV and Fufang Biejiaruangan combination therapy,and all patients were followed-up for 12 months. Serum HBV DNA loads were detected by PCR,and serum HA,PⅢP,LN and CⅣ levels were assayed routinely. All patients received Fibroscan check-up. Results At the end of 12 month observation,serum bilirubin and ALT levels in the observation group were (19.7±13.4) μmol/L and (28.3±9.4) U/L,much lower than [(23.2±13.8) μmol/L and (53.6±10.2)U/L,P<0.05] in the control,and serum albumin level was (37.2±5.6) g/L,prothrombin time activity (PTA) was (91.1±11.2)%,much higher than [(34.7±6.1)g/L and (81.4±10.5)%,P<0.05] in the control;the CTP score was (6.3±1.2),much lower than [(8.1±1.4),P<0.05] in the control,and liver stiffness measurement (LSM) was(16.5±12.2) kPa,also much lower than [(22.7±14.4)kPa,P<0.05] in the control;serum HA level was (89.2±43.1) μg/L,PⅢP level was (119.7±60.8) μg/L,LN level was (98.7±30.2) μg/L,and CⅣ level was (102.6±29.7) μg/L,significantly lower than [(184.3±58.2) μg/L,(254.5±74.7) μg/L,(140.8±39.7) μg/L,and (165.7±41.2) μg/L,respectively,P<0.05] in the control;serum HBV DNA loss was 97.5%(39/40),and it was 94.4% (34/36) in the control,without significant difference between the two groups(P>0.05),and serum HBV DNA load was(3.2±0.3) log10 copies/ml,no significant difference as compared to(3.5±0.4) log10 copies/ml in the control(P>0.05);the incidences of ascites,hepatic encephalopathy,gastrointestinal bleeding and hepatocellular carcinoma in the observation group were 17.5%,5.0%,10.0% and 2.5%,much lower than 52.7%,13.8%,16.7% and 11.1% (P<0.05) in the control;no one in the observation group but three patients(8.3%) in the control died within the 12 month observation. Conclusion The combination of ETV and Fufang Biejiaruangan compound therapy in patients with hepatitis B-induced liver cirrhosis might improve liver functions,alleviate liver cirrhosis,and improve the prognosis,which needs further and long-term investigation.

Key words: Liver cirrhosis, Hepatitis B, Fufang Biejiaruangan compound, herbal medicine, Efficacy, Prognosis